Company: IVHI
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001683168-25-003408
Chunk: 7

Company: Invech Holdings, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
24, 2000,
the agreement was terminated because the Company was unable to raise sufficient capital required under the merger agreement and was unable
to make payment to Cashsurfers under the terms of the agreement. As a result of the merger and subsequent termination was dilution of
stock ownership percentage for our existing shareholders, increased debt, and loss of our business model.

 9 

On October 5, 2000, the Company entered into an Acquisition
Agreement with UWANTCASH.com, Inc. whereby the Company acquired 100% of the issued and outstanding common and preferred shares of UWANTCASH.com,
Inc. in exchange for five million shares of common stock in IVHI. The acquisition agreement was terminated on December 6, 2000. The Company
has no operations at that time. As a result of the termination of a second merger within a six-month period, our stock was further diluted,
and our debt increased because we had no operations.

In 2001 the Company effected a 1 for 10 reverse stock
split and on May 15, 2002, the Company entered into an agreement to acquire the Access Network Limited subsidiary of VOIP Telecom, Inc.,
in exchange for the issuance of 8,000,000 shares to shareholders and owners of Access stock and an additional 4,000,000 shares to Keppel
Corp. to extinguish a debt due by Access to Keppel. In addition, IVHI issued 2,00,000 shares as a finder’s fee. Shortly after, the
Company completed a rescission agreement whereby the acquisition was cancelled. All company shares issued for debt settlements were cancelled.

 On March 17, 2003, the Company acquired the
majority interest in Hubei Pharmaceutical Co. Ltd. The Company issued 22,000,000 common shares resulting in a change in control.

On September 10th, 2004, the Company entered
into material agreement, to sell its 57.14% controlling interest in the Hubei Pharmaceutical Co. Ltd. At that time the Company was engaged
in the acquisition and vertical integration of operating subsidiaries and controlling joint venture interests in China to include all
facets of pharmaceutical life sciences from raw materials through dosage form production and distribution. In October 2005, the Company
terminated its participation in the Hubei Tongji Benda Ebei Pharmaceutical Co. Ltd. joint venture in Hubei Province, China. As a result
of